O objetivo principal do tratamento para enxaqueca é encontrar um tratamento confiável, efetivo e rápido para ataques agudos, capaz de restaurar a capacidade do indivíduo de desempenhar suas atividades.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
O tratamento deve corresponder à gravidade da cefaleia e da incapacidade do paciente.
O tratamento agudo no início da crise de enxaqueca geralmente resulta em melhor resposta, e o tratamento durante a fase pródromo pode ser razoável.[80]Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023 Dec 16;402(10419):2307-16.
http://www.ncbi.nlm.nih.gov/pubmed/37979595?tool=bestpractice.com
O tratamento preventivo é recomendado para pacientes que têm crises frequentes ou para os quais os tratamentos agudos são ineficazes ou não podem ser tolerados.
Os planos de tratamento devem ser individualizados para levar em conta fatores como as necessidades médicas, história de tratamento, preferências e objetivos do paciente, evidências de eficácia, tolerabilidade, potenciais efeitos adversos, contraindicações, comorbidades, interações medicamentosas e os efeitos de um tratamento na capacidade funcional, incapacidade e qualidade de vida do paciente.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
O Questionário de Avaliação de Incapacidade de Enxaqueca (MIDAS) é uma ferramenta validada de 5 perguntas que fornece ao médico uma avaliação objetiva do impacto relacionado à cefaleia na vida diária do paciente.[81]Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 suppl 1):S20-8.
http://www.ncbi.nlm.nih.gov/pubmed/11294956?tool=bestpractice.com
Em idosos, condições comórbidas, interações medicamentosas e efeitos adversos que afetam a cognição e a capacidade funcional dos pacientes são cada vez mais importantes.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[83]Hugger SS, Do TP, Ashina H, et al. Migraine in older adults. Lancet Neurol. 2023 Oct;22(10):934-45.
http://www.ncbi.nlm.nih.gov/pubmed/37717587?tool=bestpractice.com
O tratamento da enxaqueca em gestantes requer considerações especiais.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
[85]Ovadia C. Prescribing for pregnancy: managing chronic headache and migraine. Drug Ther Bull. 2021 Oct;59(10):152-6.
http://www.ncbi.nlm.nih.gov/pubmed/34413163?tool=bestpractice.com
Alívio dos sintomas
O tratamento deve ser iniciado assim que o paciente reconhece que está a começar um ataque de enxaqueca típico, mesmo que os sintomas sejam leves. Pode ser necessário repetir o tratamento mais tarde durante o ataque.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
Se náuseas e vômitos forem sintomas significativos, a terapia com antieméticos pode ser benéfica.[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
A desidratação é um fator desencadeante para ataques de enxaqueca e as náuseas e vômitos da enxaqueca podem levar a uma desidratação significativa. Portanto, a hidratação com fluidoterapia intravenosa deve ser considerada em qualquer paciente com enxaqueca que esteja com cefaleia prolongada associada a náuseas e vômitos.[87]Gupta S, Oosthuizen R, Pulfrey S. Treatment of acute migraine in the emergency department. Can Fam Physician. 2014 Jan;60(1):47-9.
http://www.ncbi.nlm.nih.gov/pubmed/24452560?tool=bestpractice.com
A hidratação melhora o conforto e pode acelerar a resolução de uma enxaqueca.
sintomas leves
O tratamento de enxaquecas é frequentemente iniciado pelos próprios pacientes sem nenhuma consulta a seus médicos. Os médicos devem estar familiarizados com a farmacologia, os benefícios clínicos e os potenciais problemas de segurança dos medicamentos de venda livre usados no automanejo da enxaqueca.
Os medicamentos de venda livre com eficácia comprovada para enxaqueca incluem anti-inflamatórios não esteroidais (AINEs), como aspirina, ibuprofeno ou diclofenaco. O paracetamol é menos eficaz.[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[88]Sico JJ, Antonovich NM, Ballard-Hernandez J, et al. 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice guideline for the management of headache. Ann Intern Med. 2024 Dec;177(12):1675-94.
https://www.acpjournals.org/doi/10.7326/ANNALS-24-00551
http://www.ncbi.nlm.nih.gov/pubmed/39467289?tool=bestpractice.com
A combinação patenteada de aspirina/paracetamol/cafeína é mais eficaz do que placebo e analgésicos de venda livre para sintomas leves a moderados.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[89]Lipton RB, Diener HC, Robbins MS, et al. Caffeine in the management of patients with headache. J Headache Pain. 2017 Oct 24;18(1):107.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655397
http://www.ncbi.nlm.nih.gov/pubmed/29067618?tool=bestpractice.com
[90]Diener HC, Gaul C, Lehmacher W, et al. Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: a systemic review and meta-analysis of randomized placebo-controlled trials. Eur J Neurol. 2022 Jan;29(1):350-7.
https://onlinelibrary.wiley.com/doi/10.1111/ene.15103
http://www.ncbi.nlm.nih.gov/pubmed/34519136?tool=bestpractice.com
Os AINEs prescritos, como aspirina, diclofenaco, ibuprofeno e naproxeno, demonstraram ser tratamentos iniciais eficazes.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[91]Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008783.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008783.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/23633360?tool=bestpractice.com
[92]Rabbie RD, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008039.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008039.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/23633348?tool=bestpractice.com
[93]Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010 May;50(5):808-18.
http://www.ncbi.nlm.nih.gov/pubmed/20236345?tool=bestpractice.com
[94]Becker WJ, Findlay T, Moga C, et al. Guideline for primary care management of headache in adults. Can Fam Physician. 2015 Aug;61(8):670-9.
https://headachesociety.ca/wp-content/uploads/2017/12/Becker-Can-Fam-Physician-2015.pdf
http://www.ncbi.nlm.nih.gov/pubmed/26273080?tool=bestpractice.com
[95]Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 suppl 3):S1-S80.
https://headachesociety.ca/wp-content/uploads/2017/12/Worthington-acute-migraine-guideline-CJNS-2013.pdf
http://www.ncbi.nlm.nih.gov/pubmed/23968886?tool=bestpractice.com
[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
[
]
How does diclofenac affect outcomes in adults with acute migraine headaches?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.458/fullMostre-me a resposta
[
]
In adults with acute migraine headaches, what are the effects of ibuprofen?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.210/fullMostre-me a resposta
Se os AINEs forem contraindicados ou não forem tolerados, ou se a paciente estiver grávida, o paracetamol poderá ser usado.[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
[94]Becker WJ, Findlay T, Moga C, et al. Guideline for primary care management of headache in adults. Can Fam Physician. 2015 Aug;61(8):670-9.
https://headachesociety.ca/wp-content/uploads/2017/12/Becker-Can-Fam-Physician-2015.pdf
http://www.ncbi.nlm.nih.gov/pubmed/26273080?tool=bestpractice.com
Ele é mais eficaz que o placebo no tratamento da enxaqueca, mas pode ser menos eficaz que outros analgésicos simples. A combinação de paracetamol com metoclopramida é equivalente à sumatriptana oral em termos de eficácia em curto prazo, mas com menos efeitos adversos.[97]Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008040.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008040.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/23633349?tool=bestpractice.com
[
]
What are the benefits and harms of acetaminophen (paracetamol) with or without an antiemetic in adults with acute migraine headaches?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.216/fullMostre-me a resposta
As evidências da eficácia dos opioides na enxaqueca aguda são limitadas e seu uso deve ser evitado.[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
sintomas moderados a graves
O tratamento inicial é realizado com um medicamento específico para enxaqueca.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
Triptanos
Triptanos (agonistas do receptor 5HT1) são o tratamento de primeira linha para pacientes com enxaqueca moderada a grave.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
[88]Sico JJ, Antonovich NM, Ballard-Hernandez J, et al. 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice guideline for the management of headache. Ann Intern Med. 2024 Dec;177(12):1675-94.
https://www.acpjournals.org/doi/10.7326/ANNALS-24-00551
http://www.ncbi.nlm.nih.gov/pubmed/39467289?tool=bestpractice.com
[98]Karlsson WK, Ostinelli EG, Zhuang ZA, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ. 2024 Sep 18;386:e080107.
https://www.bmj.com/content/386/bmj-2024-080107
http://www.ncbi.nlm.nih.gov/pubmed/39293828?tool=bestpractice.com
Eles são eficazes e geralmente bem tolerados, embora estejam associados a um risco maior de qualquer evento adverso ou de um evento adverso relacionado ao tratamento, em comparação com placebo e não triptanos.[99]Thorlund K, Toor K, Wu P, et al. Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. 2017 Sep;37(10):965-78.
http://www.ncbi.nlm.nih.gov/pubmed/27521843?tool=bestpractice.com
Os triptanos são contraindicados em pacientes com doença arterial coronariana e devem ser usados com cautela em pacientes com fatores de risco cardiovascular.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[100]Petersen CL, Hougaard A, Gaist D, et al. Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol. 2024 Mar 1;81(3):248-54.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2814687
http://www.ncbi.nlm.nih.gov/pubmed/38315477?tool=bestpractice.com
O tratamento logo no início com triptanos, enquanto a cefaleia ainda é leve, aumenta a probabilidade de alívio total da dor, reduz o risco de cefaleia recorrente, reduz a quantidade de medicamento necessária para tratar o ataque inteiro.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
[95]Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 suppl 3):S1-S80.
https://headachesociety.ca/wp-content/uploads/2017/12/Worthington-acute-migraine-guideline-CJNS-2013.pdf
http://www.ncbi.nlm.nih.gov/pubmed/23968886?tool=bestpractice.com
Foi demonstrado que todos os triptanos orais são eficazes no tratamento agudo da enxaqueca, e a escolha depende de fatores como disponibilidade e preferência do paciente.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
[98]Karlsson WK, Ostinelli EG, Zhuang ZA, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ. 2024 Sep 18;386:e080107.
https://www.bmj.com/content/386/bmj-2024-080107
http://www.ncbi.nlm.nih.gov/pubmed/39293828?tool=bestpractice.com
[101]Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev. 2014 May 28;2014(5):CD009108.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009108.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/24865446?tool=bestpractice.com
Vias alternativas de administração (por exemplo, sumatriptana subcutânea ou intranasal, zolmitriptana intranasal) demonstraram ser eficazes para crises agudas de enxaqueca. Essas formulações são particularmente úteis para pacientes com náuseas ou vômitos intensos ou que têm dificuldade para deglutir.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[101]Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev. 2014 May 28;2014(5):CD009108.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009108.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/24865446?tool=bestpractice.com
A resposta individual do paciente a qualquer triptano específico não pode ser predita, portanto, se um triptano for ineficaz, um segundo deve ser testado.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
Caso o tratamento com um triptano isolado não seja eficaz o suficiente, um AINE, paracetamol ou paracetamol/aspirina/cafeína pode ser usado como terapia adjuvante. Isso melhora a eficácia do tratamento agudo, com um aumento mínimo nos efeitos adversos.[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
[95]Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 suppl 3):S1-S80.
https://headachesociety.ca/wp-content/uploads/2017/12/Worthington-acute-migraine-guideline-CJNS-2013.pdf
http://www.ncbi.nlm.nih.gov/pubmed/23968886?tool=bestpractice.com
[102]Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD008541.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008541.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/27096438?tool=bestpractice.com
[103]Krymchantowski AV. The use of combination therapies in the acute management of migraine. Neuropsychiatr Dis Treat. 2006 Sep;2(3):293-7.
https://www.doi.org/10.2147/nedt.2006.2.3.293
http://www.ncbi.nlm.nih.gov/pubmed/19412476?tool=bestpractice.com
Lasmiditano e antagonistas do peptídeo relacionado ao gene da calcitonina (CGRP)
O lasmiditano e os antagonistas orais/intranasais do CGRP (também conhecidos como gepants) são eficazes para o tratamento agudo de enxaqueca com ou sem aura em adultos e são opções de segunda linha recomendadas se os triptanos forem ineficazes ou contraindicados.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[88]Sico JJ, Antonovich NM, Ballard-Hernandez J, et al. 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice guideline for the management of headache. Ann Intern Med. 2024 Dec;177(12):1675-94.
https://www.acpjournals.org/doi/10.7326/ANNALS-24-00551
http://www.ncbi.nlm.nih.gov/pubmed/39467289?tool=bestpractice.com
[104]de Boer I, Verhagen IE, Souza MNP, et al. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia. 2023 Feb;43(2):3331024221143773.
https://journals.sagepub.com/doi/10.1177/03331024221143773
http://www.ncbi.nlm.nih.gov/pubmed/36739516?tool=bestpractice.com
[105]National Institute for Health and Care Excellence. Rimegepant for treating migraine. Oct 2023 [internet publication].
https://www.nice.org.uk/guidance/ta919
Esses medicamentos não contraem os vasos sanguíneos e parecem ser seguros para pacientes com doenças cardiovasculares.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
Se o tratamento com qualquer uma dessas terapias isoladamente não for suficientemente eficaz, um AINE, paracetamol ou paracetamol/aspirina/cafeína pode ser usado como terapia adjuvante.
O lasmiditano, um agonista do receptor de serotonina 5-HT1F de primeira classe, foi associado em ensaios a melhoras significativas na ausência de dor, alívio da dor e alívio do sintoma mais incômodo 2 horas após a administração, bem como na ausência de dor em 1 dia e 1 semana (em comparação com placebo).[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
[106]Anderson CC, VanderPluym JH. Profile of lasmiditan in the acute treatment of migraine in adults: design, development, and place in therapy. Drug Des Devel Ther. 2023;17:1979-93.
https://www.dovepress.com/profile-of-lasmiditan-in-the-acute-treatment-of-migraine-in-adults-des-peer-reviewed-fulltext-article-DDDT
http://www.ncbi.nlm.nih.gov/pubmed/37426628?tool=bestpractice.com
Os efeitos adversos relatados foram, em sua maioria, leves (por exemplo, tontura, parestesia, sonolência, fadiga), embora tenha sido observado comprometimento clinicamente significativo no desempenho da condução de veículos. Os pacientes são aconselhados a não dirigir por pelo menos 8 horas após o uso de lasmiditano.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
[106]Anderson CC, VanderPluym JH. Profile of lasmiditan in the acute treatment of migraine in adults: design, development, and place in therapy. Drug Des Devel Ther. 2023;17:1979-93.
https://www.dovepress.com/profile-of-lasmiditan-in-the-acute-treatment-of-migraine-in-adults-des-peer-reviewed-fulltext-article-DDDT
http://www.ncbi.nlm.nih.gov/pubmed/37426628?tool=bestpractice.com
Os antagonistas orais de CGRP incluem rimegepant e ubrogepant. Rimegepant e ubrogepant foram associados a melhoras significativas na ausência de dor, alívio da dor e do sintoma mais incômodo (não relacionado à dor) em 2 horas, bem como ausência de dor sustentada em 1 dia e em 1 semana em ensaios versus placebo.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
Eles demonstraram boa segurança e tolerabilidade em ensaios e estão associados a menos efeitos adversos do que o lasmiditano.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[107]Puledda F, Younis S, Huessler EM, et al. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia. 2023 Mar;43(3):3331024231151419.
https://journals.sagepub.com/doi/10.1177/03331024231151419
http://www.ncbi.nlm.nih.gov/pubmed/36786357?tool=bestpractice.com
Em um estudo, o ubrogepant foi significativamente mais eficaz que o placebo na eliminação da cefaleia quando administrado durante a fase pródromo.[80]Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023 Dec 16;402(10419):2307-16.
http://www.ncbi.nlm.nih.gov/pubmed/37979595?tool=bestpractice.com
Zavegepant é um antagonista intranasal de CGRP. O zavegepant foi associado em ensaios com melhoras significativas na dor e no alívio dos sintomas em comparação ao placebo, e tem menos efeitos adversos do que outras terapias intranasais específicas para tratar enxaqueca aguda.[108]Waqas M, Ansari FUR, Nazir A, et al. Zavegepant nasal spray for the acute treatment of migraine: a meta analysis. Medicine (Baltimore). 2023 Oct 27;102(43):e35632.
https://journals.lww.com/md-journal/fulltext/2023/10270/zavegepant_nasal_spray_for_the_acute_treatment_of.118.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37904462?tool=bestpractice.com
[109]Li G, Duan S, Zhu T, et al. Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. J Headache Pain. 2023 Sep 18;24(1):129.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01662-6
http://www.ncbi.nlm.nih.gov/pubmed/37723470?tool=bestpractice.com
Derivados de ergot
Os derivados do ergot são aprovados para o tratamento agudo da enxaqueca, embora triptanos, lasmiditano ou antagonistas do CGRP sejam as opções de medicamentos de primeira escolha em comparação aos derivados do ergot para a maioria dos pacientes que necessitam de tratamento específico para enxaqueca, devido à eficácia superior e ao menor número de efeitos adversos.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[86]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024 Aug;44(8):3331024241252666.
https://journals.sagepub.com/doi/10.1177/03331024241252666
http://www.ncbi.nlm.nih.gov/pubmed/39133176?tool=bestpractice.com
[110]Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000 Jan;123(Pt 1):9-18.
http://brain.oxfordjournals.org/cgi/content/full/123/1/9
http://www.ncbi.nlm.nih.gov/pubmed/10611116?tool=bestpractice.com
[111]Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009 Sep;16(9):968-81.
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1468-1331.2009.02748.x
http://www.ncbi.nlm.nih.gov/pubmed/19708964?tool=bestpractice.com
A di-hidroergotamina é o único medicamento da categoria usado comumente nos EUA para tratar a enxaqueca. Os derivados do ergot não devem ser usados com triptanos. Caso o tratamento com um derivativo de ergot isolado não seja eficaz o suficiente, um AINE, paracetamol ou paracetamol/aspirina/cafeína pode ser usado como terapia adjuvante.
Neuromodulação não invasiva
Dispositivos neuromoduladores podem ser considerados como uma opção para tratar enxaqueca aguda se os triptanos forem ineficazes ou contraindicados e/ou se um tratamento não oral for necessário devido a náuseas ou vômitos intensos. Além disso, a neuromodulação adjuvante pode reduzir a medicação aguda e, assim, diminuir o risco de cefaleia por uso excessivo de medicamentos. As abordagens que se mostraram eficazes e aprovadas para o tratamento da enxaqueca aguda são a estimulação elétrica do nervo trigêmeo, a estimulação do nervo vago não invasiva, a estimulação magnética transcraniana de pulso único e a neuromodulação elétrica remota.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
[112]Clark O, Mahjoub A, Osman N, et al. Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials. Neurol Sci. 2022 Jan;43(1):153-65.
http://www.ncbi.nlm.nih.gov/pubmed/34698941?tool=bestpractice.com
[113]Feng Y, Zhang B, Zhang J, et al. Effects of non-invasive brain stimulation on headache intensity and frequency of headache attacks in patients with migraine: a systematic review and meta-analysis. Headache. 2019 Oct;59(9):1436-47.
http://www.ncbi.nlm.nih.gov/pubmed/31535368?tool=bestpractice.com
Medicação de resgate para enxaqueca intensa
O tratamento de primeira linha de adultos com enxaqueca aguda no pronto-socorro deve incluir um antiemético intravenoso (por exemplo, metoclopramida ou proclorperazina) com ou sem difenidramina.[114]Orr SL, Friedman BW, Christie SC, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016 Jun;56(6):911-40.
https://onlinelibrary.wiley.com/doi/full/10.1111/head.12835
http://www.ncbi.nlm.nih.gov/pubmed/27300483?tool=bestpractice.com
[115]Golikhatir I, Cheraghmakani H, Bozorgi F, et al. The efficacy and safety of prochlorperazine in patients with acute migraine: a systematic review and meta-analysis. Headache. 2019 May;59(5):682-700.
http://www.ncbi.nlm.nih.gov/pubmed/30990883?tool=bestpractice.com
[116]Friedman BW, Cabral L, Adewunmi V, et al. Diphenhydramine as adjuvant therapy for acute migraine: an emergency department-based randomized clinical trial. Ann Emerg Med. 2016 Jan;67(1):32-9.e3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695376
http://www.ncbi.nlm.nih.gov/pubmed/26320523?tool=bestpractice.com
[117]D'Souza RS, Mercogliano C, Ojukwu E, et al. Effects of prophylactic anticholinergic medications to decrease extrapyramidal side effects in patients taking acute antiemetic drugs: a systematic review and meta-analysis. Emerg Med J. 2018 May;35(5):325-31.
https://emj.bmj.com/content/35/5/325.long
http://www.ncbi.nlm.nih.gov/pubmed/29431143?tool=bestpractice.com
A prometazina pode também ser usada para alívio sintomático de náuseas. Evidências sugerem que ela possa aliviar outros sintomas da enxaqueca. A proclorperazina parece agir mais rapidamente que a prometazina, mas tem desfechos semelhantes em 60 minutos.[118]Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012 Feb;52(2):292-306.
http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.02070.x/full
http://www.ncbi.nlm.nih.gov/pubmed/22309235?tool=bestpractice.com
As diretrizes da American Headache Society (AHS) recomendam oferecer a sumatriptana subcutânea. E defendem também a administração intravenosa de cetorolaco, ácido valproico, haloperidol ou paracetamol.[114]Orr SL, Friedman BW, Christie SC, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016 Jun;56(6):911-40.
https://onlinelibrary.wiley.com/doi/full/10.1111/head.12835
http://www.ncbi.nlm.nih.gov/pubmed/27300483?tool=bestpractice.com
O uso de opioides deve ser evitado porque há risco de dependência, uso indevido ou superdosagem, e outros tratamentos parecem mais eficazes.[96]VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69.
https://jamanetwork.com/journals/jama/fullarticle/2781052
http://www.ncbi.nlm.nih.gov/pubmed/34128998?tool=bestpractice.com
[114]Orr SL, Friedman BW, Christie SC, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016 Jun;56(6):911-40.
https://onlinelibrary.wiley.com/doi/full/10.1111/head.12835
http://www.ncbi.nlm.nih.gov/pubmed/27300483?tool=bestpractice.com
A hidratação com fluidoterapia intravenosa deve ser considerada em qualquer paciente com cefaleia enxaquecosa prolongada associada a náuseas e vômitos.[87]Gupta S, Oosthuizen R, Pulfrey S. Treatment of acute migraine in the emergency department. Can Fam Physician. 2014 Jan;60(1):47-9.
http://www.ncbi.nlm.nih.gov/pubmed/24452560?tool=bestpractice.com
O oxigênio em sistema de alto fluxo pode fornecer tratamento agudo eficaz para enxaqueca.[119]Ozkurt B, Cinar O, Cevik E, et al. Efficacy of high-flow oxygen therapy in all types of headache: a prospective, randomized, placebo-controlled trial. Amer J Emerg Med. 2012 Nov;30(9):1760-4.
http://www.ncbi.nlm.nih.gov/pubmed/22560101?tool=bestpractice.com
Corticosteroide intravenoso
Um corticosteroide intravenoso, como dexametasona, deve ser oferecido para evitar a recorrência de enxaqueca.[114]Orr SL, Friedman BW, Christie SC, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016 Jun;56(6):911-40.
https://onlinelibrary.wiley.com/doi/full/10.1111/head.12835
http://www.ncbi.nlm.nih.gov/pubmed/27300483?tool=bestpractice.com
Embora o uso frequente possa resultar em supressão adrenal, osteoporose, osteonecrose ou elevação da glicose sérica, o risco de efeitos adversos irreversíveis, como osteonecrose, é extremamente baixo após uma dose de dexametasona.[114]Orr SL, Friedman BW, Christie SC, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016 Jun;56(6):911-40.
https://onlinelibrary.wiley.com/doi/full/10.1111/head.12835
http://www.ncbi.nlm.nih.gov/pubmed/27300483?tool=bestpractice.com
magnésio intravenoso
O magnésio intravenoso pode ser considerado para pacientes selecionados.
Baixos níveis cerebrais e séricos de magnésio ionizado foram demonstrados em algumas pessoas com enxaqueca.[120]Boska MD, Welch KM, Barker PB, et al. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology. 2002 Apr 23;58(8):1227-33.
http://www.ncbi.nlm.nih.gov/pubmed/11971091?tool=bestpractice.com
Uma revisão sistemática sugeriu potenciais benefícios de controle da dor após 1 hora, duração da aura e necessidade de analgesia de resgate, mas observou evidências conflitantes.[121]Miller AC, K Pfeffer B, Lawson MR, et al. Intravenous magnesium sulfate to treat acute headaches in the emergency department: a systematic review. Headache. 2019 Nov;59(10):1674-86.
http://www.ncbi.nlm.nih.gov/pubmed/31566727?tool=bestpractice.com
As diretrizes da AHS indicam que não é possível fazer nenhuma recomendação relativa ao uso de magnésio intravenoso para adultos que chegam ao pronto-socorro com enxaqueca aguda, mas que pode ser benéfico para pacientes com enxaqueca com aura.[114]Orr SL, Friedman BW, Christie SC, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016 Jun;56(6):911-40.
https://onlinelibrary.wiley.com/doi/full/10.1111/head.12835
http://www.ncbi.nlm.nih.gov/pubmed/27300483?tool=bestpractice.com
Tratamento agudo da enxaqueca na gestação
Mulheres com enxaqueca devem receber aconselhamento pré-concepção.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
[85]Ovadia C. Prescribing for pregnancy: managing chronic headache and migraine. Drug Ther Bull. 2021 Oct;59(10):152-6.
http://www.ncbi.nlm.nih.gov/pubmed/34413163?tool=bestpractice.com
A neuromodulação não invasiva é um potencial tratamento não farmacológico para enxaqueca aguda durante a gravidez, embora a eficácia em gestantes não tenha sido avaliada e as evidências de seu uso na gravidez sejam limitadas.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
Caso seja necessário um tratamento para enxaqueca durante a gestação, o medicamento mais seguro deve ser recomendado na dose mais baixa pela menor duração possível para alcançar o controle eficaz dos sintomas.[85]Ovadia C. Prescribing for pregnancy: managing chronic headache and migraine. Drug Ther Bull. 2021 Oct;59(10):152-6.
http://www.ncbi.nlm.nih.gov/pubmed/34413163?tool=bestpractice.com
Paracetamol é recomendado como terapia inicial para o tratamento da enxaqueca aguda.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
Para enxaqueca persistente, o uso de metoclopramida isoladamente ou combinado com difenidramina é recomendado pelo American College of Obstetricians and Gynecologists (ACOG).[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
A difenidramina também pode ser usada em conjunto com a proclorperazina.
AINEs para enxaqueca não tratável só podem ser considerados no segundo trimestre. Sumatriptana pode ser considerada com precaução, mas não é adequada para pacientes com doença cardíaca ou hipertensão.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
Uma revisão sistemática concluiu que os triptanos não parecem aumentar o risco de desfechos adversos na gravidez.[123]Dudman DC, Tauqeer F, Kaur M, et al. A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project. J Neurol. 2022 Feb;269(2):742-9.
http://www.ncbi.nlm.nih.gov/pubmed/33792783?tool=bestpractice.com
O magnésio intravenoso pode ser considerado para pacientes com enxaqueca que não apresentaram resposta a outras terapias, mas apenas como tratamento de curto prazo, pois pode causar adelgaçamento ósseo no feto em desenvolvimento quando usado por mais de 5 a 7 dias seguidos.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
[124]US Food and Drug Administration. FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. May 2013 [internet publication].
https://www.fda.gov/downloads/Drugs/DrugSafety/UCM353335.pdf
Prednisolona oral é o corticosteroide de escolha para uso na gestação, devido ao seu perfil de segurança, embora sua eficácia possa ser menor que a da dexametasona. A dexametasona pode ser considerada com precaução para pacientes gestantes com enxaqueca recalcitrante grave.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
Há pouca informação disponível sobre a segurança do lasmiditano ou dos antagonistas do CGRP na gestação, e eles não são atualmente recomendados para gestantes.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
Derivados do ergot, aspirina em doses analgésicas e opioides não são recomendados para tratar enxaqueca na gestação.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
[85]Ovadia C. Prescribing for pregnancy: managing chronic headache and migraine. Drug Ther Bull. 2021 Oct;59(10):152-6.
http://www.ncbi.nlm.nih.gov/pubmed/34413163?tool=bestpractice.com
O ácido valproico e seus derivados são contraindicados durante a gestação.
Tratamento preventivo: princípios
A consideração do tratamento preventivo é recomendada se qualquer um dos seguintes se aplicar: as crises de enxaqueca interferem significativamente nas atividades diárias do paciente, apesar do tratamento agudo; crises frequentes; contraindicação, efeitos adversos, falha ou uso excessivo de tratamentos agudos.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
A prevenção inclui evitar fatores desencadeantes e fazer uso de terapias farmacológicas e não farmacológicas específicas.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
A escolha do tratamento preventivo deve ser individualizada, baseada em eficácia comprovada, nas preferências do paciente e no perfil da cefaleia, nos efeitos adversos do medicamento e na presença ou ausência de comorbidades clínicas coexistentes, inclusive gestação.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[125]Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024 Apr;64(4):333-41.
https://www.doi.org/10.1111/head.14692
http://www.ncbi.nlm.nih.gov/pubmed/38466028?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[127]Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 4 Feb 2025 [Epub ahead of print].
https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
http://www.ncbi.nlm.nih.gov/pubmed/39899861?tool=bestpractice.com
Evitar o gatilho
Vários fatores podem agir como fatores desencadeantes de enxaqueca em alguns pacientes. No entanto, na maioria dos casos, os dados são provenientes de pesquisas com pacientes, e não há evidências suficientes de ensaios clínicos randomizados e controlados.
Os fatores desencadeantes relatados incluem:
Alto consumo de cafeína. A cafeína aumenta o risco de enxaqueca e enxaqueca crônica, especialmente em mulheres mais jovens e em indivíduos com cefaleias crônicas de início recente. A supressão súbita de cafeína também pode desencadear ataques de enxaqueca.[128]Hindiyeh NA, Zhang N, Farrar M, et al. The role of diet and nutrition in migraine triggers and treatment: a systematic literature review. Headache. 2020 Jul;60(7):1300-16.
https://www.doi.org/10.1111/head.13836
http://www.ncbi.nlm.nih.gov/pubmed/32449944?tool=bestpractice.com
[129]Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022 Oct;21(10):911-21.
http://www.ncbi.nlm.nih.gov/pubmed/36115363?tool=bestpractice.com
[130]Nowaczewska M, Wiciński M, Kaźmierczak W. The ambiguous role of caffeine in migraine headache: from trigger to treatment. Nutrients. 2020 Jul 28;12(8):2259.
https://www.mdpi.com/2072-6643/12/8/2259/htm
http://www.ncbi.nlm.nih.gov/pubmed/32731623?tool=bestpractice.com
Alimentos específicos e bebidas alcoólicas. Estudos de pesquisas com pacientes sugeriram fatores desencadeantes alimentares para a enxaqueca. As evidências preliminares sugerem que alterações na dieta podem melhorar a frequência ou a intensidade da cefaleia, mas as evidências são fracas e isso deve ser investigado em ensaios clínicos randomizados e controlados.[128]Hindiyeh NA, Zhang N, Farrar M, et al. The role of diet and nutrition in migraine triggers and treatment: a systematic literature review. Headache. 2020 Jul;60(7):1300-16.
https://www.doi.org/10.1111/head.13836
http://www.ncbi.nlm.nih.gov/pubmed/32449944?tool=bestpractice.com
[129]Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022 Oct;21(10):911-21.
http://www.ncbi.nlm.nih.gov/pubmed/36115363?tool=bestpractice.com
Mudanças climáticas. Mudanças na temperatura, umidade e/ou pressão atmosférica podem desencadear enxaqueca em alguns pacientes.[129]Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022 Oct;21(10):911-21.
http://www.ncbi.nlm.nih.gov/pubmed/36115363?tool=bestpractice.com
[131]Marmura MJ. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018 Oct 5;22(12):81.
http://www.ncbi.nlm.nih.gov/pubmed/30291562?tool=bestpractice.com
Altitudes elevadas. Há evidências de que altitudes elevadas aumentam a prevalência e a intensidade da enxaqueca.[129]Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022 Oct;21(10):911-21.
http://www.ncbi.nlm.nih.gov/pubmed/36115363?tool=bestpractice.com
[131]Marmura MJ. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018 Oct 5;22(12):81.
http://www.ncbi.nlm.nih.gov/pubmed/30291562?tool=bestpractice.com
[132]Linde M, Edvinsson L, Manandhar K, et al. Migraine associated with altitude: results from a population-based study in Nepal. Eur J Neurol. 2017 Aug;24(8):1055-61.
https://www.doi.org/10.1111/ene.13334
http://www.ncbi.nlm.nih.gov/pubmed/28556384?tool=bestpractice.com
Odores específicos. Perfumes ou odores foram relatados como fatores desencadeantes de enxaqueca.[131]Marmura MJ. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018 Oct 5;22(12):81.
http://www.ncbi.nlm.nih.gov/pubmed/30291562?tool=bestpractice.com
Os pacientes devem aprender como evitar o fator desencadeante e devem ser estimulados a manter um diário de cefaleia, para que os fatores desencadeantes possam ser identificados e evitados. Entretanto, em alguns casos, evitar os fatores desencadeantes pode não ser realista.[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[129]Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022 Oct;21(10):911-21.
http://www.ncbi.nlm.nih.gov/pubmed/36115363?tool=bestpractice.com
Tratamento preventivo: terapias não farmacológicas
As terapias não farmacológicas são especialmente apropriadas para mulheres gestantes ou que tentam engravidar e outras pessoas que desejam evitar ou não toleram terapia medicamentosa.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
O sono inadequado, estresse, depressão, ansiedade e abuso de medicamentos são fatores de risco para desfechos desfavoráveis em estudos prospectivos; tratamentos não farmacológicos ou consulta com especialista para tratar esses problemas podem melhorar os resultados.[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[129]Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022 Oct;21(10):911-21.
http://www.ncbi.nlm.nih.gov/pubmed/36115363?tool=bestpractice.com
Terapias biocomportamentais
Várias formas de terapia biocomportamental são recomendadas para a prevenção da enxaqueca, incluindo terapia cognitivo-comportamental, biofeedback e treinamento de relaxamento.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[133]Dudeney J, Sharpe L, McDonald S, et al. Are psychological interventions efficacious for adults with migraine? a systematic review and meta-analysis. Headache. 2022 Apr;62(4):405-19.
http://www.ncbi.nlm.nih.gov/pubmed/35122436?tool=bestpractice.com
Terapias baseadas em atenção plena também têm algumas evidências de eficácia.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
No entanto, uma revisão Cochrane de 2019 concluiu que as evidências sobre terapias psicológicas para a prevenção da enxaqueca em adultos são de baixa qualidade, o que dificulta chegar a conclusões sobre sua eficácia.[134]Sharpe L, Dudeney J, Williams ACC, et al. Psychological therapies for the prevention of migraine in adults. Cochrane Database Syst Rev. 2019 Jul 2;(7):CD012295.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012295.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/31264211?tool=bestpractice.com
Neuromodulação não invasiva
A estimulação externa do nervo trigêmeo, a estimulação do nervo vago não invasiva e estimulação magnética transcraniana de pulso único têm evidências de eficácia e são aprovados para o tratamento preventivo da enxaqueca.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[135]Moisset X, Pereira B, Ciampi de Andrade D, et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2020 Dec 10;21(1):142.
https://www.doi.org/10.1186/s10194-020-01204-4
http://www.ncbi.nlm.nih.gov/pubmed/33302882?tool=bestpractice.com
As diretrizes recomendam considerar uma tentativa com um dispositivo neuromodulador para prevenção como adjuvante ao plano de tratamento existente para todos os pacientes com enxaqueca. A neuromodulação também pode ser benéfica como monoterapia para pacientes que precisam ou preferem limitar ou evitar medicamentos devido a contraindicações ou baixa tolerabilidade.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
Atividade física
Há algumas evidências de que exercícios aeróbios, ioga e treinamento de força podem diminuir a frequência da enxaqueca e o número de dias de enxaqueca.[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[136]Woldeamanuel YW, Oliveira ABD. What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? a systematic review and network meta-analysis of clinical trials. J Headache Pain. 2022 Oct 13;23(1):134.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01503-y
http://www.ncbi.nlm.nih.gov/pubmed/36229774?tool=bestpractice.com
[137]La Touche R, Fierro-Marrero J, Sánchez-Ruíz I, et al. Prescription of therapeutic exercise in migraine, an evidence-based clinical practice guideline. J Headache Pain. 2023 Jun 7;24(1):68.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01571-8
http://www.ncbi.nlm.nih.gov/pubmed/37286937?tool=bestpractice.com
[138]Long C, Ye J, Chen M, et al. Effectiveness of yoga therapy for migraine treatment: a meta-analysis of randomized controlled studies. Am J Emerg Med. 2022 Aug;58:95-9.
http://www.ncbi.nlm.nih.gov/pubmed/35660369?tool=bestpractice.com
[139]Wu Q, Liu P, Liao C, et al. Effectiveness of yoga therapy for migraine: a meta-analysis of randomized controlled studies. J Clin Neurosci. 2022 May;99:147-51.
http://www.ncbi.nlm.nih.gov/pubmed/35279587?tool=bestpractice.com
As evidências da eficácia das terapias físicas (por exemplo, massagem, fisioterapia, tratamento quiroprático) são muito limitadas, e mais pesquisas são necessárias.[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[140]Onan D, Ekizoğlu E, Arıkan H, et al. The efficacy of physical therapy and rehabilitation approaches in chronic migraine: a systematic review and meta-analysis. J Integr Neurosci. 2023 Aug 16;22(5):126.
https://www.imrpress.com/journal/JIN/22/5/10.31083/j.jin2205126/htm
http://www.ncbi.nlm.nih.gov/pubmed/37735140?tool=bestpractice.com
Acupuntura
De acordo com uma revisão Cochrane, a adição de acupuntura ao tratamento sintomático dos ataques reduziu a frequência das cefaleias; contudo, em comparação com o tratamento medicamentoso profilático, esse efeito não foi mantido no acompanhamento (3 meses).[141]Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev. 2016 Jun 28;(6):CD001218.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001218.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/27351677?tool=bestpractice.com
Outras revisões sistemáticas sugeriram que a acupuntura pode ser um tratamento profilático seguro e eficaz para a enxaqueca, mas a qualidade das evidências é baixa.[142]Guo W, Cui H, Zhang L, et al. Acupuncture for the treatment of migraine: an overview of systematic reviews. Curr Pain Headache Rep. 2023 Aug;27(8):239-57.
http://www.ncbi.nlm.nih.gov/pubmed/37329483?tool=bestpractice.com
[143]Li M, Wang W, Gao W, et al. Comparison of acupuncture and sham acupuncture in migraine treatment: an overview of systematic reviews. Neurologist. 2022 May 1;27(3):111-8.
https://journals.lww.com/theneurologist/fulltext/2022/05000/comparison_of_acupuncture_and_sham_acupuncture_in.5.aspx
http://www.ncbi.nlm.nih.gov/pubmed/34842579?tool=bestpractice.com
A acupuntura pode ser útil para pacientes que não desejam usar medicamentos profiláticos ou para quem os medicamentos profiláticos são ineficazes.[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
Tratamento preventivo: terapias farmacológicas
Os antagonistas de CGRP são recomendados como terapia farmacológica de primeira linha para prevenção da enxaqueca pela American Headache Society (AHS); há evidências substanciais de sua eficácia, segurança e tolerabilidade, em comparação com outras terapias de primeira linha.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[125]Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024 Apr;64(4):333-41.
https://www.doi.org/10.1111/head.14692
http://www.ncbi.nlm.nih.gov/pubmed/38466028?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[127]Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 4 Feb 2025 [Epub ahead of print].
https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
http://www.ncbi.nlm.nih.gov/pubmed/39899861?tool=bestpractice.com
[144]Giri S, Tronvik E, Linde M, et al. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta-analysis. Cephalalgia. 2023 Apr;43(4):3331024231156922.
https://journals.sagepub.com/doi/10.1177/03331024231156922
http://www.ncbi.nlm.nih.gov/pubmed/36856015?tool=bestpractice.com
[145]Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023 May 19;24(1):56.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01594-1
http://www.ncbi.nlm.nih.gov/pubmed/37208596?tool=bestpractice.com
[146]Mistry H, Naghdi S, Brown A, et al. Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. Health Technol Assess. 2024 Oct;28(63):1-329.
https://www.journalslibrary.nihr.ac.uk/hta/AYWA5297#full-report
http://www.ncbi.nlm.nih.gov/pubmed/39365169?tool=bestpractice.com
[147]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024 Sep;44(9):3331024241269735.
https://journals.sagepub.com/doi/10.1177/03331024241269735
http://www.ncbi.nlm.nih.gov/pubmed/39262214?tool=bestpractice.com
Os antagonistas de CGRP para profilaxia de enxaqueca incluem antagonistas orais de CGRP (também conhecidos como gepants) e anticorpos monoclonais antagonistas de CGRP.[125]Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024 Apr;64(4):333-41.
https://www.doi.org/10.1111/head.14692
http://www.ncbi.nlm.nih.gov/pubmed/38466028?tool=bestpractice.com
Outros tratamentos medicamentosos usados para prevenção da enxaqueca incluem anticonvulsivantes (por exemplo, divalproato de sódio, topiramato), betabloqueadores, candesartana (um antagonista do receptor de angiotensina II), antidepressivos tricíclicos (por exemplo, amitriptilina) e inibidores da recaptação de serotonina-noradrenalina (IRSNs; por exemplo, venlafaxina, duloxetina).[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[82]Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505-18.
http://www.ncbi.nlm.nih.gov/pubmed/33773612?tool=bestpractice.com
[88]Sico JJ, Antonovich NM, Ballard-Hernandez J, et al. 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice guideline for the management of headache. Ann Intern Med. 2024 Dec;177(12):1675-94.
https://www.acpjournals.org/doi/10.7326/ANNALS-24-00551
http://www.ncbi.nlm.nih.gov/pubmed/39467289?tool=bestpractice.com
[125]Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024 Apr;64(4):333-41.
https://www.doi.org/10.1111/head.14692
http://www.ncbi.nlm.nih.gov/pubmed/38466028?tool=bestpractice.com
[127]Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 4 Feb 2025 [Epub ahead of print].
https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
http://www.ncbi.nlm.nih.gov/pubmed/39899861?tool=bestpractice.com
[147]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024 Sep;44(9):3331024241269735.
https://journals.sagepub.com/doi/10.1177/03331024241269735
http://www.ncbi.nlm.nih.gov/pubmed/39262214?tool=bestpractice.com
[
]
Can topiramate help to prevent episodic migraine in adults?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1481/fullMostre-me a resposta
O tratamento deve ser iniciado em doses baixas e reavaliado após um período de avaliação adequado (pelo menos 8 semanas).[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
A duração ideal do tratamento preventivo é desconhecida. Uma vez que um tratamento eficaz é encontrado, a maioria dos especialistas recomenda continuá-lo por pelo menos 4 a 6 meses. Nesse período, a dose pode ser lentamente reduzida ao longo de semanas ou meses enquanto qualquer alteração na frequência das cefaleias é monitorada, retomando-se o tratamento integral quando necessário.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
Alguns pacientes cujas cefaleias são extremamente incapacitantes ou problemáticas podem preferir permanecer indefinidamente no tratamento preventivo.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
No entanto, a tolerância a terapias preventivas pode limitar sua eficiência.[148]Rizzoli P, Loder EW. Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache. 2011 Sep;51(8):1323-35.
http://www.ncbi.nlm.nih.gov/pubmed/21884087?tool=bestpractice.com
Antagonistas de CGRP
Os antagonistas de CGRP são uma opção de primeira linha para prevenção da enxaqueca.[125]Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024 Apr;64(4):333-41.
https://www.doi.org/10.1111/head.14692
http://www.ncbi.nlm.nih.gov/pubmed/38466028?tool=bestpractice.com
Os antagonistas orais de CGRP para profilaxia da enxaqueca incluem atogepant e rimegepant.[125]Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024 Apr;64(4):333-41.
https://www.doi.org/10.1111/head.14692
http://www.ncbi.nlm.nih.gov/pubmed/38466028?tool=bestpractice.com
Foi demonstrado em ensaios clínicos que ambos os medicamentos reduzem o número médio de dias de enxaqueca por mês.[145]Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023 May 19;24(1):56.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01594-1
http://www.ncbi.nlm.nih.gov/pubmed/37208596?tool=bestpractice.com
[149]Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Sep 2;402(10404):775-85.
http://www.ncbi.nlm.nih.gov/pubmed/37516125?tool=bestpractice.com
[150]Dos Santos JBR, da Silva MRR. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: a review. Eur J Pharmacol. 2022 May 5;922:174902.
http://www.ncbi.nlm.nih.gov/pubmed/35358493?tool=bestpractice.com
[151]Singh A, Balasundaram MK. Atogepant for migraine prevention: a systematic review of efficacy and safety. Clin Drug Investig. 2022 Apr;42(4):301-8.
http://www.ncbi.nlm.nih.gov/pubmed/35230651?tool=bestpractice.com
[152]Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024 Apr;23(4):382-92.
http://www.ncbi.nlm.nih.gov/pubmed/38364831?tool=bestpractice.com
[153]Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology. 2024 Jul 23;103(2):e209584.
https://www.neurology.org/doi/10.1212/WNL.0000000000209584
http://www.ncbi.nlm.nih.gov/pubmed/38924724?tool=bestpractice.com
Eles são geralmente seguros e bem tolerados para prevenção de enxaqueca.[154]Messina R, Huessler EM, Puledda F, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023 Mar;43(3):3331024231152169.
https://journals.sagepub.com/doi/10.1177/03331024231152169
http://www.ncbi.nlm.nih.gov/pubmed/36786548?tool=bestpractice.com
Anticorpos monoclonais antagonistas de CGRP (por exemplo, erenumabe, fremanezumabe, galcanezumabe, eptinezumabe) são outra opção. Eles são administrados por via subcutânea ou intravenosa, dependendo do medicamento. Foi demonstrado em ensaios clínicos randomizados e controlados que todos os quatro medicamentos reduzem os dias mensais de enxaqueca em pacientes com enxaqueca episódica ou crônica, e são seguros e bem tolerados.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[144]Giri S, Tronvik E, Linde M, et al. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta-analysis. Cephalalgia. 2023 Apr;43(4):3331024231156922.
https://journals.sagepub.com/doi/10.1177/03331024231156922
http://www.ncbi.nlm.nih.gov/pubmed/36856015?tool=bestpractice.com
[145]Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023 May 19;24(1):56.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01594-1
http://www.ncbi.nlm.nih.gov/pubmed/37208596?tool=bestpractice.com
[154]Messina R, Huessler EM, Puledda F, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023 Mar;43(3):3331024231152169.
https://journals.sagepub.com/doi/10.1177/03331024231152169
http://www.ncbi.nlm.nih.gov/pubmed/36786548?tool=bestpractice.com
[155]Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022 Jun 11;23(1):67.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01431-x
http://www.ncbi.nlm.nih.gov/pubmed/35690723?tool=bestpractice.com
[156]Aleksovska K, Hershey AD, Deen M, et al. Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society. Cephalalgia. 2023 Oct;43(10):3331024231206162.
https://journals.sagepub.com/doi/10.1177/03331024231206162
http://www.ncbi.nlm.nih.gov/pubmed/37879637?tool=bestpractice.com
[157]Pozo-Rosich P, Dolezil D, Paemeleire K, et al. Early use of erenumab vs nonspecific oral migraine preventives: the APPRAISE randomized clinical trial. JAMA Neurol. 2024 May 1;81(5):461-70.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2816800
http://www.ncbi.nlm.nih.gov/pubmed/38526461?tool=bestpractice.com
Dados do mundo real dão suporte aos resultados dos ensaios clínicos, embora as evidências sejam limitadas.[158]Pavelic AR, Wöber C, Riederer F, et al. Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells. 2022 Dec 29;12(1):143.
https://www.mdpi.com/2073-4409/12/1/143
http://www.ncbi.nlm.nih.gov/pubmed/36611935?tool=bestpractice.com
Há evidências preliminares de que a troca para um anticorpo monoclonal antagonista de CGRP alternativo após a ausência de resposta ao primeiro pode ser eficaz para alguns pacientes.[159]Straube A, Broessner G, Gaul C, et al. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study. J Headache Pain. 2023 May 23;24(1):59.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01593-2
http://www.ncbi.nlm.nih.gov/pubmed/37221478?tool=bestpractice.com
[160]Overeem LH, Lange KS, Fitzek MP, et al. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol. 2023;14:1154420.
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1154420/full
http://www.ncbi.nlm.nih.gov/pubmed/37034092?tool=bestpractice.com
[161]Talbot J, Stuckey R, Wood N, et al. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab. Eur J Hosp Pharm. 2025 Feb 21;32(2):178-85.
http://www.ncbi.nlm.nih.gov/pubmed/38182276?tool=bestpractice.com
Anticonvulsivantes
O topiramato é recomendado para a prevenção da enxaqueca.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[127]Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 4 Feb 2025 [Epub ahead of print].
https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
http://www.ncbi.nlm.nih.gov/pubmed/39899861?tool=bestpractice.com
[147]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024 Sep;44(9):3331024241269735.
https://journals.sagepub.com/doi/10.1177/03331024241269735
http://www.ncbi.nlm.nih.gov/pubmed/39262214?tool=bestpractice.com
[162]Medrea I, Cooper P, Langman M, et al. Updated Canadian Headache Society migraine prevention guideline with systematic review and meta-analysis. Can J Neurol Sci. 7 Nov 2024 [Epub ahead of print].
https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/updated-canadian-headache-society-migraine-prevention-guideline-with-systematic-review-and-metaanalysis/34704719E8C0A1ADBEF030D6176036FF
http://www.ncbi.nlm.nih.gov/pubmed/39506371?tool=bestpractice.com
[163]Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012 Apr 24;78(17):1337-45.
https://n.neurology.org/content/78/17/1337
http://www.ncbi.nlm.nih.gov/pubmed/22529202?tool=bestpractice.com
[
]
Can topiramate help to prevent episodic migraine in adults?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1481/fullMostre-me a resposta É eficaz na redução dos dias de cefaleia enxaquecosa e geralmente é bem tolerado, embora eventos adversos possam resultar na descontinuação do tratamento.[164]Raffaelli B, García-Azorín D, Boucherie DM, et al. European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate. J Headache Pain. 2023 Oct 10;24(1):134.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01671-5
http://www.ncbi.nlm.nih.gov/pubmed/37814223?tool=bestpractice.com
O topiramato não preveniu o desenvolvimento de cefaleia crônica diária em 6 meses em um estudo.[165]Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011 Jan;31(1):18-30.
http://www.ncbi.nlm.nih.gov/pubmed/20974598?tool=bestpractice.com
Ele está associado à perda de peso e é especialmente útil em pacientes com excesso de peso ou que não estão dispostos a tomar medicamentos que possam causar aumento de peso.
A exposição ao topiramato durante a gestação está associada a transtornos do neurodesenvolvimento infantil e malformações congênitas.[166]Bjørk MH, Zoega H, Leinonen MK, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022 Jul 1;79(7):672-81.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2793003
http://www.ncbi.nlm.nih.gov/pubmed/35639399?tool=bestpractice.com
[167]Marmura MJ. Safety of topiramate for treating migraines. Expert Opin Drug Saf. 2014 Sep;13(9):1241-7.
http://www.ncbi.nlm.nih.gov/pubmed/25096056?tool=bestpractice.com
Em alguns países, o topiramato é contraindicado na gestação e para mulheres em idade fértil, a menos que as condições de um programa de prevenção da gestação sejam atendidas para garantir que as mulheres em idade fértil: estejam usando métodos de contracepção altamente eficazes; tenham feito um teste de gravidez para descartar gravidez antes de iniciar o tratamento com topiramato; e estejam cientes dos riscos associados ao uso do medicamento.[168]Gov.UK. Topiramate (topamax): introduction of new safety measures, including a pregnancy prevention programme.Jun 2024 [internet publication].
https://www.gov.uk/drug-safety-update/topiramate-topamax-introduction-of-new-safety-measures-including-a-pregnancy-prevention-programme
[169]European Medicines Agency. PRAC recommends new measures to avoid topiramate exposure in pregnancy. Sep 2023 [internet publication].
https://www.ema.europa.eu/en/news/prac-recommends-new-measures-avoid-topiramate-exposure-pregnancy
O divalproato de sódio (um derivado do ácido valproico) também é recomendado para prevenção da enxaqueca.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[127]Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 4 Feb 2025 [Epub ahead of print].
https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
http://www.ncbi.nlm.nih.gov/pubmed/39899861?tool=bestpractice.com
[147]Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024 Sep;44(9):3331024241269735.
https://journals.sagepub.com/doi/10.1177/03331024241269735
http://www.ncbi.nlm.nih.gov/pubmed/39262214?tool=bestpractice.com
[163]Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012 Apr 24;78(17):1337-45.
https://n.neurology.org/content/78/17/1337
http://www.ncbi.nlm.nih.gov/pubmed/22529202?tool=bestpractice.com
[170]Cui XY, Sun SM, Liu J, et al. The efficacy and safety of valproate medications for migraine in adults: a meta-analysis. Eur Rev Med Pharmacol Sci. 2020 May;24(10):5734-41.
http://www.ncbi.nlm.nih.gov/pubmed/32495909?tool=bestpractice.com
O ácido valproico e seus derivados podem causar malformações congênitas graves, incluindo transtornos do neurodesenvolvimento e defeitos do tubo neural, após uma exposição intra-útero.
Esses agentes não devem ser usados em pacientes do sexo feminino em idade fértil, a menos que outras opções não sejam adequadas, exista um programa de prevenção da gravidez e certas condições sejam atendidas.
Medidas de precaução também podem ser necessárias em pacientes do sexo masculino devido ao risco potencial de que o uso nos 3 meses anteriores à concepção possa aumentar a probabilidade de transtornos do neurodesenvolvimento em seus filhos.
Os regulamentos e medidas de precaução para pacientes do sexo feminino e masculino podem variar entre os países, com alguns países adotando uma postura de precaução mais rigorosa, e você deve consultar as orientações locais para obter mais informações.
Betabloqueadores
Propranolol, timolol, metoprolol, nadolol e atenolol demonstraram evidências de benefícios.[28]National Institute for Health and Care Excellence. Headaches in over 12s: diagnosis and management. May 2021 [internet publication].
https://www.nice.org.uk/guidance/cg150
[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[163]Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012 Apr 24;78(17):1337-45.
https://n.neurology.org/content/78/17/1337
http://www.ncbi.nlm.nih.gov/pubmed/22529202?tool=bestpractice.com
[171]Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012 Jun;52(6):930-45.
http://www.ncbi.nlm.nih.gov/pubmed/22671714?tool=bestpractice.com
[172]Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785.
https://www.doi.org/10.1371/journal.pone.0212785
http://www.ncbi.nlm.nih.gov/pubmed/30893319?tool=bestpractice.com
candesartana
Ensaios clínicos randomizados e controlados demonstraram que o candesartana (um antagonista do receptor de angiotensina II) é eficaz na prevenção da enxaqueca.[173]Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014 Jun;34(7):523-32.
https://journals.sagepub.com/doi/10.1177/0333102413515348?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
http://www.ncbi.nlm.nih.gov/pubmed/24335848?tool=bestpractice.com
[174]Messina R, Lastarria Perez CP, Filippi M, et al. Candesartan in migraine prevention: results from a retrospective real-world study. J Neurol. 2020 Nov;267(11):3243-7.
http://www.ncbi.nlm.nih.gov/pubmed/32542525?tool=bestpractice.com
[175]Sánchez-Rodríguez C, Sierra Á, Planchuelo-Gómez Á, et al. Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. Sci Rep. 2021 Feb 15;11(1):3846.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7884682
http://www.ncbi.nlm.nih.gov/pubmed/33589682?tool=bestpractice.com
Antidepressivos tricíclicos
Acredita-se que os antidepressivos tricíclicos previnem a enxaqueca ao inibir a recaptação de serotonina e noradrenalina. Nenhum antidepressivo tricíclico é aprovado nos EUA para prevenção de enxaqueca. Foi relatado que a amitriptilina é eficaz na prevenção da enxaqueca, mas os ensaios clínicos têm sido de baixa qualidade.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[127]Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 4 Feb 2025 [Epub ahead of print].
https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
http://www.ncbi.nlm.nih.gov/pubmed/39899861?tool=bestpractice.com
[176]Lampl C, Versijpt J, Amin FM, et al. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline. J Headache Pain. 2023 Apr 11;24(1):39.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01573-6
http://www.ncbi.nlm.nih.gov/pubmed/37038134?tool=bestpractice.com
IRSNs
Há dados que sugerem que a venlafaxina é tão eficaz quanto a amitriptilina na prevenção da enxaqueca.[177]Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004 Dec;107(1):44-8.
http://www.ncbi.nlm.nih.gov/pubmed/15567552?tool=bestpractice.com
Também há evidências de que a duloxetina é eficaz na prevenção da enxaqueca.[127]Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 4 Feb 2025 [Epub ahead of print].
https://www.acpjournals.org/doi/10.7326/ANNALS-24-01052
http://www.ncbi.nlm.nih.gov/pubmed/39899861?tool=bestpractice.com
[178]Kisler LB, Weissman-Fogel I, Coghill RC, et al. Individualization of migraine prevention: a randomized controlled trial of psychophysical-based prediction of duloxetine efficacy. Clin J Pain. 2019 Sep;35(9):753-5.
http://www.ncbi.nlm.nih.gov/pubmed/31241488?tool=bestpractice.com
[179]Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol. 2019 Mar 21;21(4):18.
http://www.ncbi.nlm.nih.gov/pubmed/30895388?tool=bestpractice.com
Esses medicamentos podem ser especialmente úteis para pacientes com depressão comórbida.
Toxina botulínica tipo A
Foi demonstrado que a toxina botulínica tipo A reduz as crises de enxaqueca em comparação ao placebo, é bem tolerada e melhora a qualidade de vida.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[146]Mistry H, Naghdi S, Brown A, et al. Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. Health Technol Assess. 2024 Oct;28(63):1-329.
https://www.journalslibrary.nihr.ac.uk/hta/AYWA5297#full-report
http://www.ncbi.nlm.nih.gov/pubmed/39365169?tool=bestpractice.com
[180]Shaterian N, Shaterian N, Ghanaatpisheh A, et al. Botox (onabotulinumtoxinA) for treatment of migraine symptoms: a systematic review Pain Res Manag. 2022;2022:3284446.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8989603
http://www.ncbi.nlm.nih.gov/pubmed/35401888?tool=bestpractice.com
[181]Lanteri-Minet M, Ducros A, Francois C, et al. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. Cephalalgia. 2022 Dec;42(14):1543-64.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9693763
http://www.ncbi.nlm.nih.gov/pubmed/36081276?tool=bestpractice.com
[
]
How does botulinum toxin type A compare with placebo for preventing migraine in adults?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2241/fullMostre-me a resposta É recomendada como uma opção de tratamento para prevenção de enxaqueca nas diretrizes dos EUA.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
Também é recomendada para o tratamento de enxaqueca crônica (cefaleia que ocorre em ≥15 dias por mês durante >3 meses) nas diretrizes europeias e canadenses.[162]Medrea I, Cooper P, Langman M, et al. Updated Canadian Headache Society migraine prevention guideline with systematic review and meta-analysis. Can J Neurol Sci. 7 Nov 2024 [Epub ahead of print].
https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/updated-canadian-headache-society-migraine-prevention-guideline-with-systematic-review-and-metaanalysis/34704719E8C0A1ADBEF030D6176036FF
http://www.ncbi.nlm.nih.gov/pubmed/39506371?tool=bestpractice.com
[182]Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018 Sep 26;19(1):91.
https://www.doi.org/10.1186/s10194-018-0921-8
http://www.ncbi.nlm.nih.gov/pubmed/30259200?tool=bestpractice.com
A resposta ao tratamento deve ser avaliada regularmente, levando em consideração que todos os efeitos desaparecerão com o tempo, e o tratamento deve ser interrompido se o paciente não apresentar resposta aos primeiros dois ou três ciclos de tratamento.[182]Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018 Sep 26;19(1):91.
https://www.doi.org/10.1186/s10194-018-0921-8
http://www.ncbi.nlm.nih.gov/pubmed/30259200?tool=bestpractice.com
O tratamento combinado com um anticorpo monoclonal antagonista de CGRP pode ser mais eficaz do que o tratamento com toxina botulínica isoladamente.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[126]Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022 Oct 10;379:e067670.
https://www.doi.org/10.1136/bmj-2021-067670
http://www.ncbi.nlm.nih.gov/pubmed/36216384?tool=bestpractice.com
[183]Scuteri D, Tonin P, Nicotera P, et al. Pooled analysis of real-world evidence supports anti-CGRP mAbs and onabotulinumtoxinA combined trial in chronic migraine. Toxins (Basel). 2022 Aug 1;14(8):529.
https://www.mdpi.com/2072-6651/14/8/529
http://www.ncbi.nlm.nih.gov/pubmed/36006191?tool=bestpractice.com
Medicação preventiva para mulheres com enxaqueca menstrual
Pode-se considerar a terapia hormonal em mulheres com enxaqueca menstrual, com o objetivo de suprimir a menstruação, caso isso seja clinicamente apropriado.[27]Ceriani CEJ, Silberstein SD. Current and emerging pharmacotherapy for menstrual migraine: a narrative review. Expert Opin Pharmacother. 2023 Apr;24(5):617-27.
http://www.ncbi.nlm.nih.gov/pubmed/36946205?tool=bestpractice.com
[184]Sacco S, Merki-Feld GS, Ægidius KL, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018 Aug 31;19(1):76.
https://www.doi.org/10.1186/s10194-018-0896-5
http://www.ncbi.nlm.nih.gov/pubmed/30171365?tool=bestpractice.com
Uma história completa deve ser obtida e os Critérios Clínicos de Elegibilidade para uso de contraceptivos devem ser aplicados para determinar o uso seguro de contraceptivos para supressão menstrual.[185]American College of Obstetricians and Gynecologists. General approaches to medical management of menstrual suppression. Sep 2022 [internet publication].
https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2022/09/general-approaches-to-medical-management-of-menstrual-suppression
Os contraceptivos hormonais combinados são contraindicados para mulheres que sofrem de enxaqueca com aura, pois elevam o risco de eventos cerebrovasculares.[186]Sacco S, Merki-Feld GS, Ægidius KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017 Oct 30;18(1):108.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662520
http://www.ncbi.nlm.nih.gov/pubmed/29086160?tool=bestpractice.com
Deve-se oferecer a mulheres com enxaqueca com aura tratamentos farmacológicos além do controle do ciclo.
Evidências mostram que frovatriptana é eficaz e zolmitriptana e naratriptana são provavelmente eficazes para a prevenção em curto prazo da enxaqueca menstrual.[27]Ceriani CEJ, Silberstein SD. Current and emerging pharmacotherapy for menstrual migraine: a narrative review. Expert Opin Pharmacother. 2023 Apr;24(5):617-27.
http://www.ncbi.nlm.nih.gov/pubmed/36946205?tool=bestpractice.com
[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[163]Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012 Apr 24;78(17):1337-45.
https://n.neurology.org/content/78/17/1337
http://www.ncbi.nlm.nih.gov/pubmed/22529202?tool=bestpractice.com
[187]Zhang H, Qi JZ, Zhang ZH. Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis. J Headache Pain. 2023 Jul 3;24(1):81.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01625-x
http://www.ncbi.nlm.nih.gov/pubmed/37400775?tool=bestpractice.com
O magnésio por via oral pode ser usado como tratamento preventivo da cefaleia enxaquecosa em mulheres com cefaleias relacionadas à menstruação.[188]von Luckner A, Riederer F. Magnesium in migraine prophylaxis - is there an evidence-based rationale? A systematic review. Headache. 2018 Feb;58(2):199-209.
http://www.ncbi.nlm.nih.gov/pubmed/29131326?tool=bestpractice.com
Tratamento preventivo para gestantes
A prevenção de fatores desencadeantes e terapias não farmacológicas (por exemplo, neuromodulação não invasiva, terapias biocomportamentais) são sugeridas como tratamento preventivo de primeira linha para gestantes e mulheres planejando engravidar.[39]Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14.
https://www.nature.com/articles/s41582-021-00509-5
http://www.ncbi.nlm.nih.gov/pubmed/34145431?tool=bestpractice.com
[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
Deve-se procurar orientação de um especialista caso o tratamento farmacológico preventivo para enxaqueca seja necessário durante a gestação. Nenhum medicamento é completamente livre de riscos, e as decisões devem ser tomadas caso a caso, avaliando o risco do transtorno de cefaleia não tratado como ameaça à saúde da mãe e do feto e o risco do tratamento, e levando em consideração os valores e prioridades da paciente.[34]Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39.
https://www.doi.org/10.1111/head.14153
http://www.ncbi.nlm.nih.gov/pubmed/34160823?tool=bestpractice.com
[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
[85]Ovadia C. Prescribing for pregnancy: managing chronic headache and migraine. Drug Ther Bull. 2021 Oct;59(10):152-6.
http://www.ncbi.nlm.nih.gov/pubmed/34413163?tool=bestpractice.com
Topiramato, divalproato de sódio e candesartana são contraindicados na gravidez.
Há evidências limitadas sobre a eficácia e a segurança do uso de medicamentos para a prevenção da cefaleia na gravidez. As diretrizes do ACOG observam que os betabloqueadores têm evidências de segurança relativa na gravidez para outras indicações.[84]Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022 May 1(Reaffirmed 2024);139(5):944-72.
http://www.ncbi.nlm.nih.gov/pubmed/35576364?tool=bestpractice.com
Uma revisão concluiu que, entre os medicamentos comumente usados para a prevenção da enxaqueca, o propranolol tem a melhor evidência de segurança durante a gravidez.[189]Burch R. Headache in pregnancy and the puerperium. Neurol Clin. 2019 Feb;37(1):31-51.
http://www.ncbi.nlm.nih.gov/pubmed/30470274?tool=bestpractice.com
Uma revisão sistemática observou que anticonvulsivantes, venlafaxina, antidepressivos tricíclicos e betabloqueadores podem estar associados a efeitos adversos fetais/infantis.[190]Saldanha IJ, Cao W, Bhuma MR, et al. Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review. Headache. 2021 Jan;61(1):11-43.
https://www.doi.org/10.1111/head.14041
http://www.ncbi.nlm.nih.gov/pubmed/33433020?tool=bestpractice.com
Os antagonistas de CGRP não foram estudados em gestantes com enxaqueca. Ficou comprovado, em estudos realizados com animais, que alguns antagonistas de CGRP atravessam a placenta, mas seus efeitos sobre o desenvolvimento do feto humano são desconhecidos. Os anticorpos monoclonais antagonistas de CGRP podem ter uma meia-vida muito longa (28 dias ou mais), resultando em um tempo de eliminação prolongado após a descontinuação dos tratamentos. Planos futuros de gravidez devem ser discutidos antes de iniciar a terapia.
O magnésio não é mais recomendado como medicamento diário preventivo em gestantes com enxaqueca.[191]Tepper D. Pregnancy and lactation - migraine management. Headache. 2015 Apr;55(4):607-8.
https://americanheadachesociety.org/wp-content/uploads/2018/05/Pregnancy_and_Lactation_Toolbox.pdf
http://www.ncbi.nlm.nih.gov/pubmed/25881682?tool=bestpractice.com
Isso ocorre porque o magnésio parenteral pode causar adelgaçamento ósseo no feto em desenvolvimento quando usado por mais de 5 a 7 dias seguidos.[124]US Food and Drug Administration. FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. May 2013 [internet publication].
https://www.fda.gov/downloads/Drugs/DrugSafety/UCM353335.pdf